直接作用型抗ウイルス薬市場- 世界の産業規模、シェア、動向、機会、予測、タイプ別、適応症別、ルート別、流通チャネル別、地域別、競合別、2020-2030F

直接作用型抗ウイルス薬の世界市場規模は、2024年に114億1,000万米ドルとなり、2030年までのCAGRは12.86%で、予測期間には236億1,000万米ドルに達する見込みです。

世界の直接作用型抗ウイルス薬（DAA）市場は、ウイルス感染、特にC型肝炎の蔓延の増加により拡大しています。これらの薬剤は、特定のウイルスタンパク質を標的として複製を阻害するため、非常に有効で忍容性の高い治療選択肢を提供します。医薬品の進歩により、有効性が向上し、治療期間が短縮された次世代DAAが開発されています。ヘルスケアプロバイダーや政府がC型肝炎撲滅プログラムを優先していることから、市場は大きく成長しています。併用療法の導入は治療成績をさらに向上させ、薬剤耐性のリスクを低減し、持続的ウイルス学的奏効（SVR）率を高めています。新興諸国における診断検査と治療へのアクセスの拡大は、市場拡大に重要な役割を果たしています。

早期診断・早期治療に対する意識が高まり、政府の取り組みや非営利団体の支援を受けています。抗ウイルス薬研究への投資が増加し、安全性が向上した革新的な治療法の開発が促進されています。個別化医療へのシフトは、より高い治療成功率を保証する標的抗ウイルス療法の需要に影響を与えています。バイオテクノロジーと遺伝子研究におけるブレークスルーにより、製薬会社はより精密で強力なDAAを設計できるようになっています。注射治療よりも経口治療が好まれる傾向が強まっているため、患者のアドヒアランスが向上し、抗ウイルス治療戦略においてDAAが好ましい選択肢となっています。研究機関と製薬企業の共同研究により医薬品開発が促進され、次世代DAAsの強力なパイプラインが形成されつつあります。ヘルスケアインフラの拡大や各国における有利な償還政策が、市場プレーヤーにチャンスをもたらしています。

進歩にもかかわらず、市場は高額な治療費に関連する課題に直面しており、低所得地域の患者にとってアクセシビリティが制限されています。薬剤耐性ウイルス株の出現が懸念されており、より効果的な製剤を開発するための継続的な研究が必要とされています。規制上のハードルや新規DAAsの承認プロセスに時間がかかるため、市場参入が遅れ、技術革新サイクルに影響を及ぼす可能性があります。一部の地域では、有効な抗ウイルス治療薬が入手可能であるという認識が限定的であるため、採用率が鈍化しています。ジェネリック医薬品の存在は市場競争を激化させ、価格戦略を圧迫しています。戦略的な価格設定モデル、耐性管理の調査、世界の治療普及活動の強化を通じてこれらの課題に対処することが、市場成長を維持するために不可欠です。

主な市場促進要因

高い有効性と治癒率の向上

主な市場課題

高い治療費

主な市場動向

適応症の拡大

目次

第1章 概要

第2章 調査手法

第3章 エグゼクティブサマリー

第4章 顧客の声

第5章 世界の直接作用型抗ウイルス薬市場展望

• 市場規模・予測
  • 金額別
• 市場シェア・予測
  • タイプ別（NS3/4Aプロテアーゼ、NS5Aタンパク質、NS5B RNA依存性RNAポリメラーゼ）
  • 適応症別（C型肝炎ウイルス、HIV感染/エイズ、インフルエンザ、予防）
  • 投与経路（静脈内、経口、皮下、局所）
  • 流通チャネル別（病院薬局、小売薬局、オンライン薬局）
  • 地域別
  • 企業別（2024）
• 製品市場マップ
  • 薬の種類別
  • 適応症別
  • ルート別
  • 流通チャネル別
  • 地域別

第6章 北米の直接作用型抗ウイルス薬市場展望

• 市場規模・予測
• 市場シェア・予測
• 北米：国別分析
  • 米国
  • カナダ
  • メキシコ

第7章 欧州の直接作用型抗ウイルス薬市場展望

• 市場規模・予測
• 市場シェア・予測
• 欧州：国別分析
  • ドイツ
  • 英国
  • フランス
  • イタリア
  • スペイン

第8章 アジア太平洋地域の直接作用型抗ウイルス薬市場展望

• 市場規模・予測
• 市場シェア・予測
• アジア太平洋地域：国別分析
  • 中国
  • 日本
  • インド
  • オーストラリア
  • 韓国

第9章 南米の直接作用型抗ウイルス薬市場展望

• 市場規模・予測
• 市場シェア・予測
• 南米：国別分析
  • ブラジル
  • アルゼンチン
  • コロンビア

第10章 中東・アフリカの直接作用型抗ウイルス薬市場展望

• 市場規模・予測
• 市場シェア・予測
• 中東・アフリカ：国別分析
  • 南アフリカ
  • サウジアラビア
  • アラブ首長国連邦

第11章 市場力学

• 促進要因
• 課題

第12章 市場動向と発展

• 最近の動向
• 合併と買収
• 製品上市

第13章 ポーターのファイブフォース分析

• 業界内の競合
• 新規参入の可能性
• サプライヤーの力
• 顧客の力
• 代替品の脅威

第14章 競合情勢

• ナトコファーマ株式会社
• バーテックス・ファーマシューティカルズ
• ドクター・レディーズ・ラボラトリーズ
• ジョンソン・エンド・ジョンソン
• メルク社
• ギリアド・サイエンシズ
• アッヴィ株式会社
• ブリストル・マイヤーズスクイブ社

第15章 戦略的提言

第16章 調査会社について・免責事項

Global Direct-acting Antiviral Drug Market was valued at USD 11.41 Billion in 2024 and is expected to reach USD 23.61 Billion in the forecast period with a CAGR of 12.86% through 2030. The global direct-acting antiviral (DAA) drug market is expanding due to the increasing prevalence of viral infections, particularly hepatitis C. These drugs target specific viral proteins to inhibit replication, offering a highly effective and well-tolerated treatment option. Pharmaceutical advancements have led to the development of next-generation DAAs with improved efficacy and shorter treatment durations. The market is witnessing significant growth as healthcare providers and governments prioritize hepatitis C elimination programs. The introduction of combination therapies has further enhanced treatment outcomes, reducing the risk of drug resistance and increasing sustained virologic response (SVR) rates. Expanding access to diagnostic testing and treatment in developing countries is playing a crucial role in market expansion.

The market is benefiting from increasing awareness of early diagnosis and treatment, supported by government initiatives and non-profit organizations. Rising investments in antiviral drug research are fostering the development of innovative therapies with improved safety profiles. The shift toward personalized medicine is influencing the demand for targeted antiviral therapies, ensuring higher treatment success rates. Breakthroughs in biotechnology and genetic research are enabling pharmaceutical companies to design more precise and potent DAAs. The growing preference for oral therapies over injectable treatments is driving patient adherence, making DAAs a preferred choice in antiviral treatment strategies. Collaborations between research institutions and pharmaceutical firms are expediting drug development, leading to a robust pipeline of next-generation DAAs. Expanding healthcare infrastructure and favorable reimbursement policies in various countries are creating opportunities for market players.

Despite advancements, the market faces challenges related to high treatment costs, limiting accessibility for patients in low-income regions. The emergence of drug-resistant viral strains is a growing concern, requiring continuous research to develop more effective formulations. Regulatory hurdles and lengthy approval processes for new DAAs can delay market entry, impacting innovation cycles. Limited awareness in certain regions about the availability of effective antiviral treatments is slowing adoption rates. The presence of generic alternatives is intensifying market competition, putting pressure on pricing strategies. Addressing these challenges through strategic pricing models, research in resistance management, and increased global treatment outreach will be essential for sustaining market growth.

Key Market Drivers

High Efficacy and Improved Cure Rates

In recent years, the global pharmaceutical landscape has witnessed a transformative shift in the treatment of viral infections, particularly hepatitis C, due to the advent of direct-acting antiviral drugs (DAAs). These innovative medications have demonstrated exceptional efficacy, with cure rates exceeding 95%, redefining the approach to managing viral diseases.

The high efficacy of DAAs translates into significantly improved patient outcomes. For instance, a study published in JAMA Network Open reported that among patients treated with DAAs, 97.3% achieved sustained virologic response (SVR), indicating a cure. Successful DAA therapy not only clears the virus but also halts disease progression, reducing risks of liver fibrosis, cirrhosis, and hepatocellular carcinoma.

Beyond individual benefits, DAAs contribute to public health by reducing viral transmission. Effective treatment decreases viral load, thereby lowering the likelihood of spreading infections such as hepatitis B and C, which are transmitted through routes like blood contact and sexual intercourse. The World Health Organization highlights that DAAs can cure over 95% of hepatitis C cases, yet access to diagnosis and treatment remains limited globally.

DAAs also offer shorter treatment durations compared to traditional interferon-based therapies. While older regimens required treatment courses of up to 48 weeks, DAA therapies typically range from 8 to 12 weeks, enhancing patient compliance and reducing healthcare burdens. Furthermore, DAAs are associated with improved tolerability and fewer severe side effects, encouraging patients to complete their treatment regimens.

The success of DAAs has instilled confidence among patients and healthcare providers. For example, the U.S. Department of Health and Human Services notes that new hepatitis C treatments can cure approximately 95% of patients, significantly decreasing the likelihood of severe liver complications and reducing overall healthcare costs. This underscores the importance of expanding access to these life-saving therapies to achieve broader public health benefits.

Key Market Challenges

High Treatment Costs

One of the most significant challenges is the high cost of direct-acting antiviral drugs. While these medications are highly effective, their price tags can be prohibitive for many patients, especially in low- and middle-income countries. Striking a balance between recouping research and development costs and ensuring affordable access is a persistent challenge.

Key Market Trends

Expanded Indications

One significant trend in the DAA market is the exploration of expanded indications. While DAAs have been predominantly used to treat hepatitis C and B, researchers are investigating their efficacy against other viral infections. This could lead to the development of new DAA therapies targeting a broader range of viruses.

Key Market Players

• Natco Pharma Ltd
• Vertex Pharmaceuticals Inc
• Dr Reddy's Laboratories Ltd
• Johnson & Johnson
• Merck & Co Inc
• Gilead Sciences Inc
• AbbVie Inc
• Bristol-Myers Squibb Co

Report Scope:

In this report, the Global Direct-acting Antiviral Drug Market has been segmented into the following categories, in addition to the industry trends which have also been detailed below:

Direct-acting Antiviral Drug Market, By Type:

• NS3/4A Protease
• NS5A Protein
• NS5B RNA-Dependent RNA polymerase

Direct-acting Antiviral Drug Market, By Indication:

• Hepatitis C Virus
• HIV Infection/ AIDS
• Influenza
• Prophylaxis

Direct-acting Antiviral Drug Market, By Route:

• Intravenous
• Oral
• Subcutaneous
• Topical

Direct-acting Antiviral Drug Market, By Distribution Channel:

• Hospital Pharmacies
• Retail Pharmacies
• Online Pharmacies

Direct-acting Antiviral Drug Market, By Region:

• North America
  • United States
  • Canada
  • Mexico
• Europe
  • Germany
  • United Kingdom
  • France
  • Italy
  • Spain
• Asia-Pacific
  • China
  • Japan
  • India
  • Australia
  • South Korea
• South America
  • Brazil
  • Argentina
  • Colombia
• Middle East & Africa
  • South Africa
  • Saudi Arabia
  • UAE

Competitive Landscape

Company Profiles: Detailed analysis of the major companies present in the Global Direct-acting Antiviral Drug Market.

Available Customizations:

Global Direct-acting Antiviral Drug market report with the given market data, TechSci Research offers customizations according to a company's specific needs. The following customization options are available for the report:

Company Information

• Detailed analysis and profiling of additional market players (up to five).

Table of Contents

1. Product Overview

• 1.1. Market Definition
• 1.2. Scope of the Market
  • 1.2.1. Markets Covered
  • 1.2.2. Years Considered for Study
  • 1.2.3. Key Market Segmentations

2. Research Methodology

• 2.1. Objective of the Study
• 2.2. Baseline Methodology
• 2.3. Key Industry Partners
• 2.4. Major Association and Secondary Sources
• 2.5. Forecasting Methodology
• 2.6. Data Triangulation & Validation
• 2.7. Assumptions and Limitations

3. Executive Summary

• 3.1. Overview of the Market
• 3.2. Overview of Key Market Segmentations
• 3.3. Overview of Key Market Players
• 3.4. Overview of Key Regions/Countries
• 3.5. Overview of Market Drivers, Challenges, Trends

4. Voice of Customer

5. Global Direct-acting Antiviral Drug Market Outlook

• 5.1. Market Size & Forecast
  • 5.1.1. By Value
• 5.2. Market Share & Forecast
  • 5.2.1. By Type (NS3/4A Protease, NS5A Protein, NS5B RNA-Dependent RNA polymerase)
  • 5.2.2. By Indication (Hepatitis C Virus, HIV Infection/ AIDS, Influenza, Prophylaxis)
  • 5.2.3. By Route (Intravenous, Oral, Subcutaneous, Topical)
  • 5.2.4. By Distribution Channel (Hospital Pharmacies, Retail Pharmacies, Online Pharmacies)
  • 5.2.5. By Region
  • 5.2.6. By Company (2024)
• 5.3. Product Market Map
  • 5.3.1. By Drug Type
  • 5.3.2. By Indication
  • 5.3.3. By Route
  • 5.3.4. By Distribution Channel
  • 5.3.5. By Region

6. North America Direct-acting Antiviral Drug Market Outlook

• 6.1. Market Size & Forecast
  • 6.1.1. By Value
• 6.2. Market Share & Forecast
  • 6.2.1. By Type (NS3/4A Protease, NS5A Protein, NS5B RNA-Dependent RNA polymerase)
  • 6.2.2. By Indication (Hepatitis C Virus, HIV Infection/ AIDS, Influenza, Prophylaxis)
  • 6.2.3. By Route (Intravenous, Oral, Subcutaneous, Topical)
  • 6.2.4. By Distribution Channel (Hospital Pharmacies, Retail Pharmacies, Online Pharmacies)
  • 6.2.5. By Country
• 6.3. North America: Country Analysis
  • 6.3.1. United States Direct-acting Antiviral Drug Market Outlook
    • 6.3.1.1. Market Size & Forecast
      • 6.3.1.1.1. By Value
    • 6.3.1.2. Market Share & Forecast
      • 6.3.1.2.1. By Drug Type
      • 6.3.1.2.2. By Indication
      • 6.3.1.2.3. By Route
      • 6.3.1.2.4. By Distribution Channel
  • 6.3.2. Canada Direct-acting Antiviral Drug Market Outlook
    • 6.3.2.1. Market Size & Forecast
      • 6.3.2.1.1. By Value
    • 6.3.2.2. Market Share & Forecast
      • 6.3.2.2.1. By Drug Type
      • 6.3.2.2.2. By Indication
      • 6.3.2.2.3. By Route
      • 6.3.2.2.4. By Distribution Channel
  • 6.3.3. Mexico Direct-acting Antiviral Drug Market Outlook
    • 6.3.3.1. Market Size & Forecast
      • 6.3.3.1.1. By Value
    • 6.3.3.2. Market Share & Forecast
      • 6.3.3.2.1. By Drug Type
      • 6.3.3.2.2. By Indication
      • 6.3.3.2.3. By Route
      • 6.3.3.2.4. By Distribution Channel

7. Europe Direct-acting Antiviral Drug Market Outlook

• 7.1. Market Size & Forecast
  • 7.1.1. By Value
• 7.2. Market Share & Forecast
  • 7.2.1. By Type (NS3/4A Protease, NS5A Protein, NS5B RNA-Dependent RNA polymerase)
  • 7.2.2. By Indication (Hepatitis C Virus, HIV Infection/ AIDS, Influenza, Prophylaxis)
  • 7.2.3. By Route (Intravenous, Oral, Subcutaneous, Topical)
  • 7.2.4. By Distribution Channel (Hospital Pharmacies, Retail Pharmacies, Online Pharmacies)
  • 7.2.5. By Country
• 7.3. Europe: Country Analysis
  • 7.3.1. Germany Direct-acting Antiviral Drug Market Outlook
    • 7.3.1.1. Market Size & Forecast
      • 7.3.1.1.1. By Value
    • 7.3.1.2. Market Share & Forecast
      • 7.3.1.2.1. By Drug Type
      • 7.3.1.2.2. By Indication
      • 7.3.1.2.3. By Route
      • 7.3.1.2.4. By Distribution Channel
  • 7.3.2. United Kingdom Direct-acting Antiviral Drug Market Outlook
    • 7.3.2.1. Market Size & Forecast
      • 7.3.2.1.1. By Value
    • 7.3.2.2. Market Share & Forecast
      • 7.3.2.2.1. By Drug Type
      • 7.3.2.2.2. By Indication
      • 7.3.2.2.3. By Route
      • 7.3.2.2.4. By Distribution Channel
  • 7.3.3. France Direct-acting Antiviral Drug Market Outlook
    • 7.3.3.1. Market Size & Forecast
      • 7.3.3.1.1. By Value
    • 7.3.3.2. Market Share & Forecast
      • 7.3.3.2.1. By Drug Type
      • 7.3.3.2.2. By Indication
      • 7.3.3.2.3. By Route
      • 7.3.3.2.4. By Distribution Channel
  • 7.3.4. Italy Direct-acting Antiviral Drug Market Outlook
    • 7.3.4.1. Market Size & Forecast
      • 7.3.4.1.1. By Value
    • 7.3.4.2. Market Share & Forecast
      • 7.3.4.2.1. By Drug Type
      • 7.3.4.2.2. By Indication
      • 7.3.4.2.3. By Route
      • 7.3.4.2.4. By Distribution Channel
  • 7.3.5. Spain Direct-acting Antiviral Drug Market Outlook
    • 7.3.5.1. Market Size & Forecast
      • 7.3.5.1.1. By Value
    • 7.3.5.2. Market Share & Forecast
      • 7.3.5.2.1. By Drug Type
      • 7.3.5.2.2. By Indication
      • 7.3.5.2.3. By Route
      • 7.3.5.2.4. By Distribution Channel

8. Asia-Pacific Direct-acting Antiviral Drug Market Outlook

• 8.1. Market Size & Forecast
  • 8.1.1. By Value
• 8.2. Market Share & Forecast
  • 8.2.1. By Type (NS3/4A Protease, NS5A Protein, NS5B RNA-Dependent RNA polymerase)
  • 8.2.2. By Indication (Hepatitis C Virus, HIV Infection/ AIDS, Influenza, Prophylaxis)
  • 8.2.3. By Route (Intravenous, Oral, Subcutaneous, Topical)
  • 8.2.4. By Distribution Channel (Hospital Pharmacies, Retail Pharmacies, Online Pharmacies)
  • 8.2.5. By Country
• 8.3. Asia-Pacific: Country Analysis
  • 8.3.1. China Direct-acting Antiviral Drug Market Outlook
    • 8.3.1.1. Market Size & Forecast
      • 8.3.1.1.1. By Value
    • 8.3.1.2. Market Share & Forecast
      • 8.3.1.2.1. By Drug Type
      • 8.3.1.2.2. By Indication
      • 8.3.1.2.3. By Route
      • 8.3.1.2.4. By Distribution Channel
  • 8.3.2. Japan Direct-acting Antiviral Drug Market Outlook
    • 8.3.2.1. Market Size & Forecast
      • 8.3.2.1.1. By Value
    • 8.3.2.2. Market Share & Forecast
      • 8.3.2.2.1. By Drug Type
      • 8.3.2.2.2. By Indication
      • 8.3.2.2.3. By Route
      • 8.3.2.2.4. By Distribution Channel
  • 8.3.3. India Direct-acting Antiviral Drug Market Outlook
    • 8.3.3.1. Market Size & Forecast
      • 8.3.3.1.1. By Value
    • 8.3.3.2. Market Share & Forecast
      • 8.3.3.2.1. By Drug Type
      • 8.3.3.2.2. By Indication
      • 8.3.3.2.3. By Route
      • 8.3.3.2.4. By Distribution Channel
  • 8.3.4. Australia Direct-acting Antiviral Drug Market Outlook
    • 8.3.4.1. Market Size & Forecast
      • 8.3.4.1.1. By Value
    • 8.3.4.2. Market Share & Forecast
      • 8.3.4.2.1. By Drug Type
      • 8.3.4.2.2. By Indication
      • 8.3.4.2.3. By Route
      • 8.3.4.2.4. By Distribution Channel
  • 8.3.5. South Korea Direct-acting Antiviral Drug Market Outlook
    • 8.3.5.1. Market Size & Forecast
      • 8.3.5.1.1. By Value
    • 8.3.5.2. Market Share & Forecast
      • 8.3.5.2.1. By Drug Type
      • 8.3.5.2.2. By Indication
      • 8.3.5.2.3. By Route
      • 8.3.5.2.4. By Distribution Channel

9. South America Direct-acting Antiviral Drug Market Outlook

• 9.1. Market Size & Forecast
  • 9.1.1. By Value
• 9.2. Market Share & Forecast
  • 9.2.1. By Type (NS3/4A Protease, NS5A Protein, NS5B RNA-Dependent RNA polymerase)
  • 9.2.2. By Indication (Hepatitis C Virus, HIV Infection/ AIDS, Influenza, Prophylaxis)
  • 9.2.3. By Route (Intravenous, Oral, Subcutaneous, Topical)
  • 9.2.4. By Distribution Channel (Hospital Pharmacies, Retail Pharmacies, Online Pharmacies)
  • 9.2.5. By Country
• 9.3. South America: Country Analysis
  • 9.3.1. Brazil Direct-acting Antiviral Drug Market Outlook
    • 9.3.1.1. Market Size & Forecast
      • 9.3.1.1.1. By Value
    • 9.3.1.2. Market Share & Forecast
      • 9.3.1.2.1. By Drug Type
      • 9.3.1.2.2. By Indication
      • 9.3.1.2.3. By Route
      • 9.3.1.2.4. By Distribution Channel
  • 9.3.2. Argentina Direct-acting Antiviral Drug Market Outlook
    • 9.3.2.1. Market Size & Forecast
      • 9.3.2.1.1. By Value
    • 9.3.2.2. Market Share & Forecast
      • 9.3.2.2.1. By Drug Type
      • 9.3.2.2.2. By Indication
      • 9.3.2.2.3. By Route
      • 9.3.2.2.4. By Distribution Channel
  • 9.3.3. Colombia Direct-acting Antiviral Drug Market Outlook
    • 9.3.3.1. Market Size & Forecast
      • 9.3.3.1.1. By Value
    • 9.3.3.2. Market Share & Forecast
      • 9.3.3.2.1. By Drug Type
      • 9.3.3.2.2. By Indication
      • 9.3.3.2.3. By Route
      • 9.3.3.2.4. By Distribution Channel

10. Middle East and Africa Direct-acting Antiviral Drug Market Outlook

• 10.1. Market Size & Forecast
  • 10.1.1. By Value
• 10.2. Market Share & Forecast
  • 10.2.1. By Type (NS3/4A Protease, NS5A Protein, NS5B RNA-Dependent RNA polymerase)
  • 10.2.2. By Indication (Hepatitis C Virus, HIV Infection/ AIDS, Influenza, Prophylaxis)
  • 10.2.3. By Route (Intravenous, Oral, Subcutaneous, Topical)
  • 10.2.4. By Distribution Channel (Hospital Pharmacies, Retail Pharmacies, Online Pharmacies)
  • 10.2.5. By Country
• 10.3. MEA: Country Analysis
  • 10.3.1. South Africa Direct-acting Antiviral Drug Market Outlook
    • 10.3.1.1. Market Size & Forecast
      • 10.3.1.1.1. By Value
    • 10.3.1.2. Market Share & Forecast
      • 10.3.1.2.1. By Drug Type
      • 10.3.1.2.2. By Indication
      • 10.3.1.2.3. By Route
      • 10.3.1.2.4. By Distribution Channel
  • 10.3.2. Saudi Arabia Direct-acting Antiviral Drug Market Outlook
    • 10.3.2.1. Market Size & Forecast
      • 10.3.2.1.1. By Value
    • 10.3.2.2. Market Share & Forecast
      • 10.3.2.2.1. By Drug Type
      • 10.3.2.2.2. By Indication
      • 10.3.2.2.3. By Route
      • 10.3.2.2.4. By Distribution Channel
  • 10.3.3. UAE Direct-acting Antiviral Drug Market Outlook
    • 10.3.3.1. Market Size & Forecast
      • 10.3.3.1.1. By Value
    • 10.3.3.2. Market Share & Forecast
      • 10.3.3.2.1. By Drug Type
      • 10.3.3.2.2. By Indication
      • 10.3.3.2.3. By Route
      • 10.3.3.2.4. By Distribution Channel

11. Market Dynamics

• 11.1. Drivers
• 11.2. Challenges

12. Market Trends & Developments

• 12.1. Recent Development
• 12.2. Mergers & Acquisitions
• 12.3. Product Launches

13. Porter's Five Forces Analysis

• 13.1. Competition in the Industry
• 13.2. Potential of New Entrants
• 13.3. Power of Suppliers
• 13.4. Power of Customers
• 13.5. Threat of Substitute Products

14. Competitive Landscape

• 14.6.1. Natco Pharma Ltd
• 14.6.2. Vertex Pharmaceuticals Inc
• 14.6.3. Dr Reddy's Laboratories Ltd
• 14.6.4. Johnson & Johnson
• 14.6.5. Merck & Co Inc
• 14.6.6. Gilead Sciences Inc
• 14.6.7. AbbVie Inc
• 14.6.8. Bristol-Myers Squibb Co

15. Strategic Recommendations

16. About Us & Disclaimer